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OBJECTIVE—Mitochondrial reactive oxygen species (ROS)
plays a key role in diabetic retinopathy (DR) pathogenesis.
However, whether simvastatin decreases diabetes-induced mito-
chondrial ROS production remains uncertain. The aim of this
study was to clarify the beneﬁcial effects and mechanism of
action of simvastatin against diabetes-induced retinal vascular
damage.
RESEARCH DESIGN AND METHODS—Diabetic rats and
control animals were randomly assigned to receive simvastatin
or vehicle for 24 weeks, and bovine retinal capillary endothelial
cells (BRECs) were incubated with normal or high glucose with
or without simvastatin. Vascular endothelial growth factor
(VEGF) and peroxisome proliferator–activated receptor  coac-
tivator 1 (PGC-1) in the rat retinas or BRECs were examined
by Western blotting and real-time RT-PCR, and poly (ADP-
ribose) polymerase (PARP), and p38 MAPK were examined by
Western blotting. Mitochondrial membrane potential (m) and
ROS production were assayed using the potentiometric dye
5,5,6,6- Tetrachloro1,1,3,3-tetraethyl-benzimidazolylcarbocya-
nine iodide (JC-1) or CM-H2DCFDA ﬂuorescent probes.
RESULTS—Simvastatin signiﬁcantly upregulated PGC-1 (P 
0.01), subsequently decreased m( P  0.05) and ROS genera-
tion (P  0.01), inhibited PARP activation (P  0.01), and further
reduced VEGF expression (P  0.01) and p38 MAPK activity (P 
0.01). Those changes were associated with the decrease of retinal
vascular permeability, retinal capillary cells apoptosis, and for-
mation of acellular capillaries.
CONCLUSIONS—Simvastatin decreases diabetes-induced mi-
tochondrial ROS production and exerts protective effects against
early retinal vascular damage in diabetic rats in association with
the inhibition of mitochondrial ROS/PARP pathway mediated by
PGC-1. The understanding of the mechanisms of action of
statins has important implications in the prevention and treat-
ment of mitochondrial oxidative stress-related illness such as
DR. Diabetes 59:2315–2325, 2010
T
he 3-hydroxy-3-methylglutaryl-CoA(HMG-CoA)
reductase inhibitors, or statins, which are
extensively used in the treatment of hypercho-
lesterolemia, are potent inhibitors of choles-
terol biosynthesis (1). By inhibiting L-mevalonic acid
synthesis, statins may also decrease mitogenic responses
and antiangiogenic actions that are independent of the
cholesterol-lowering effect (2). Previous studies re-
vealed that treatment with simvastatin-attenuated leuko-
cyte-endothelial cell interactions and the subsequent
breakdown of the blood-retinal barrier via the suppression
of vascular endothelial growth factor (VEGF) induced
intercellular adhesion molecule (ICAM)-1 expression in
db/db mice retinas (2,3). Moreover, this effect is associated
with the inhibition of NADPH oxidase-mediated reactive
oxygen species (ROS) production by statins (4,5).
Progression of vascular abnormalities, in addition to
blood-retinal barrier breakdown, including the selective
loss of pericytes and formation of acellular capillaries,
characterizes early diabetic retinopathy (DR). The in-
creased VEGF expression, on one hand, leads to increased
vascular permeability whereby statins decrease retinal
vascular permeability via VEGF downregulation (3,6). On
the other hand, it is paradoxically associated with the
selective loss of pericytes and formation of acellular
capillaries as a potent survival factor for endothelial cells
in vivo (7). Therefore, there is a need to explore the
mechanisms underlying the apoptosis of vascular cells in
diabetic rats and the possible role of statins in this
process.
It has been reported that hyperglycemia-induced ROS
production is primarily associated with mitochondria and
NADPH oxidase (8), and an increase in oxidative stress in
vascular cells plays a key role in DR pathogenesis (9–11).
A strong in vivo correlation exists between ROS produc-
tion and the expression of neovascularization and growth
factors in diabetic retinas (12,13). Recently, Brownlee (16)
suggested a unifying hypothesis integrating various mech-
anisms discussed in past years that an overproduction of
mitochondrial ROS is an initiating cause in the pathogen-
esis of diabetic complications. This concept proposes that
high glucose levels (HG) in the endothelial cells lead to
overproduction of mitochondrial ROS, which then inacti-
vates glyceraldehyde-3-phosphate dehydrogenase by poly
(ADP-ribose) polymerase (PARP) activation and subse-
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evidence as to whether there is an effect of statins on
mitochondria-derived ROS under HG conditions.
Thus, the aim of this study was to investigate the
potential effect and molecular mechanisms of statins on
mitochondria-derived ROS and retinal vascular cell apo-
ptosis under HG. Our results showed that simvastatin
signiﬁcantly inhibited the increase of mitochondria-de-
rived ROS and prevented the apoptosis of retinal vascular
cells mediated by p38 MAPK through PARP under HG, in
addition to attenuating retinal vascular permeability via
downregulation of VEGF. The effect was associated with
the upregulation of peroxisome proliferator–activated re-
ceptor  coactivator-1 (PGC-1).
RESEARCH DESIGN AND METHODS
All experiments in this study comply with the requirements of the Association
for Research in Vision and Ophthalmology Statement for the Use of Animals
in Ophthalmic and Vision Research. All chemicals were reagent grade quality
and were purchased from Sigma Chemicals (St. Louis, MO), unless stated
otherwise.
Eight-week-old male Sprague-Dawley rats weighing 200 g (Shanghai
Laboratory Animal Center, Chinese Academy of Sciences) were randomly
assigned into groups receiving either 60 mg/kg streptozotocin (STZ) intraperi-
toneally or citrate buffer alone. Rats were categorized as diabetic when the
blood glucose exceeded 16.7 mmol/l at 48 h after STZ administration. Diabetic
rats were randomly assigned into groups receiving either 10 mg/kg/day
simvastatin administered via drinking water for 24 weeks or no treatment at
all. Age-matched rats that had not received STZ served as controls. All rats
were provided free access to standard rat food and drinking water. Diabetic
rats received subcutaneous insulin (Humulin-N, Eli Lilly, Indianapolis, IN)
twice weekly to maintain body weight and maximize survival rate. Every week
the plasma glucose concentrations were monitored using the glucose oxidase
technique. Plasma triglycerides and cholesterol levels were determined with a
commercially available enzyme kit (Leadman Biotech, Beijing, China). At the
end of the experiments, the eyes were resected from deeply anesthetized
animals. The right eyes were assigned for preparation of retinal digests, and
the left eyes for the extraction procedures.
Retinal digest procedures. The eyes were immediately placed in 4%
buffered paraformaldehyde for 24 h. Retinal trypsin digestion was performed
according to the method of Cogan et al. (17). Preparations of retinal vascular
networks were set onto polylysine-coated glass slides in distilled water and
then dried. The preparations were stored at 20°C until used for periodic
acid-Schiff (PAS) and hematoxylin staining. The capillary network was
evaluated to identify the number of pericytes and acellular capillaries by using
previously described quantitative methods (11).
Measurement of retinal blood vessel leakage using Evans blue dye.
Retinal blood vessel leakage was quantitated using Evans blue dye, which
noncovalently binds to plasma albumin in the blood stream (18). With the rats
under deep anesthesia, Evans blue dye was injected through the tail vein at a
dosage of 30 mg/kg. After the dye had circulated for 60 min, the chest cavity
was opened and the left heart ventricle was cannulated. After each mouse was
perfused, the eyes were enucleated, and the retinas were carefully dissected
away under an operating microscope. The weight of each retina was measured
after thorough drying in a Speed-Vac. Albumin leakage into the retinal tissue
was estimated via the measurement of extravasated Evans blue dye. Evans
blue was extracted by incubating each retina in 60 	l formamide for 18 h at
70°C. The extract was ultracentrifuged at a speed of 70,000 rpm for 45 min at
a temperature of 4°C. The absorbance of the supernatant was measured with
a spectrophotometer at 620 nm, the absorption maximum for Evans blue in
formamide. The concentration of dye in the extracts was calculated from a
standard curve of Evans blue in formamide and normalized to the dry retinal
weight.
Cell culture. The primary culture of bovine retinal capillary endothelial cells
(BRECs) was obtained as described in our previous study (11). The endothe-
lial cells generated after four passages were used in later experiments. The
cells were incubated with either normal glucose (5 mmol/l glucose), normal
glucose plus 25 mmol/l mannitol, HG (30 mmol/l glucose), normal D-glucose(5
mmol/l) plus H2O2 (500 	mol/l), HG plus PJ-34 (3 	mol/l; a potent-speciﬁc
PARP inhibitor), or HG plus simvastatin (5 	mol/l; Merck and Co., China) in
the absence or presence of either mevalonate (100 	mol/l dissolved in
ethanol), the general ROS scavenger N-acetylcysteine (NAC) (10 mmol/l), or
NAC and GW9662 (an irreversible peroxisome proliferator-activated receptor
 [PPAR] inhibitor; 20 	mol/l). The cells were washed with PBS after 72 h for
subsequent experiments.
For knockdown studies, BRECs were infected with either a control
adenovirus vector expressing green ﬂuorescent protein, or 50 nmol/l PGC-1
siRNA, as indicated, for 48 h. Adenoviruses for PGC-1 siRNA were generated
as described (19).
Mitochondrial membrane potential (m). The potentiometric dye
5,5,6,6- Tetrachloro1,1,3,3-tetraethyl-benzimidazolylcarbocyanine iodide
(JC-1; Molecular Probes) exhibits membrane potential-dependent loss as
J-aggregates (polarized mitochondria) are converted to JC-1 monomers (de-
polarized mitochondria), as indicated by the ﬂuorescence emission shift from
red to green (20). Hence, mitochondrial depolarization was determined by an
increase in the green/red ﬂuorescence intensity ratio. Mitochondrial mem-
brane potential (m) measurements were performed by ﬂow cytometry
(Coulter Epics XL, Beckman-Coulter) as described in our previous study (11).
Real-time RT-PCR. Total RNA was extracted from rat retinal tissue and
BRECs by using the TRIzol reagent (Invitrogen Life Technologies, Gaithers-
burg, MD) and stored at 80°C. The DyNAmo Flash SYBR Green qPCR Kit
(Finnzymes Oy, Espoo, Finland) was used according to the manufacturer’s
instructions. The primer sequences (sense/antisense) used were as follows:
VEGF, 5-GCGGGCTGCTGCAATG-3/5-TGCAACGCGAGTCTGTGTTT-3; PGC-
1,5 -CACCAAACCCACAGAGAACA-3/5-GGGTCATTTGGTGACTCTGG-3;

-actin, 5-GCACCGCAAATGCTTCTA-3/5-GGTCTTTACGGATGTCAACG-
3. The speciﬁcity of the ampliﬁcation product was determined by performing
a melting curve analysis. Standard curves were generated for expression of
each gene by using serial dilutions of known quantities of the corresponding
cDNA gene template. Relative quantiﬁcation of the signals was performed by
normalizing the signals of different genes with the 
-actin signal.
Western blotting. The protein concentration in the supernatant was mea-
sured using the Bio-Rad DC protein assay. Fifty micrograms of protein
obtained from each sample (retinas or BRECs) were subjected to SDS-PAGE
in a Bio-Rad miniature slab gel apparatus and electrophoretically transferred
onto a nitrocellulose membrane. The membrane was blocked in 5% nonfat
dried milk solution and incubated overnight with partially puriﬁed mouse
anti-VEGF monoclonal antibody (mAb; 1:500; Chemicon, Temecula, CA),
rabbit anti-PGC-1 mAb (1:500) (Cell Signaling Technology), rabbit anti-
phospho-p38 MAP kinase polyclonal antibody (polyAb; 1:500; Cell Signaling
Technology), or rabbit anti-PPAR polyAb (1:500) (Upstate, Millipore). Detec-
tion of 
-actin expression with a mAb (1:1,000; Sigma Chemical) was used as
an internal control to conﬁrm equivalent total protein loading. Signal intensi-
ties in the control lanes were arbitrarily assigned a value of 1.0. Western blots
were repeated 3 to 5 times and qualitatively similar results were obtained.
Statistical analysis. The experimental data are expressed as means  SD.
Group means were compared by one-way ANOVA using the GraphPad Prism
4.0 software system (GraphPad, San Diego, CA) and the statistical software
program SPSS 13.0 for Windows (Chicago, IL). Pearson correlation tests were
also performed. P values  0.05 were considered signiﬁcant in all cases.
RESULTS
Animal data. Nonfasting blood glucose, 24-h urine vol-
ume, triglycerides, and cholesterol levels were strikingly
increased in the diabetic group as compared with those in
the normal control group (P  0.01). Administration of
simvastatin did not ameliorate the severity of hyperglyce-
mia in diabetic rats. The values obtained for nonfasting
blood glucose and 24-h urine levels determined throughout
the duration of the experiment were comparable between
the two diabetic groups (diabetes and diabetes plus sim-
vastatin), but were signiﬁcantly different (P  0.01) from
those of the normal control group (Table 1). Compared
with the diabetic group, treatment with simvastatin signif-
icantly reduced the plasma triglycerides and cholesterol
levels in the diabetic rats (triglycerides, P  0.05; choles-
terol, P  0.01). Diabetic rats were treated with insulin to
prevent weight loss. Body weight in both diabetic rat
groups remained signiﬁcantly lower than those of the
nondiabetic control rats (P  0.05). Long-term simvastatin
administration did not have adverse effects on the health
or lifespan of the diabetic rats.
Alleviation of retinal vascular permeability in dia-
betic rats by simvastatin is associated with down-
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VEGF mRNA and protein were upregulated signiﬁcantly in
the retinas of diabetic rats with a concomitant increase in
retinal vascular permeability, whereas simvastatin signiﬁ-
cantly inhibited these changes (Fig. 1A–C). Pearson cor-
relation tests showed signiﬁcant positive correlations
between the changes in retinal vascular permeability and
the changes in VEGF expression in diabetic rats with or
without treatment with simvastatin (data not shown).
Simvastatin-mediated decrease of apoptosis of reti-
nal capillary cells in diabetic rats is associated with
reduced activation of p38 MAPK. Accelerated death of
capillary cells is believed to be the major cause of acellular
capillary formation (21). Compared with the control rats,
the number of pericytes and endothelial cells signiﬁcantly
decreased (P  0.01), and that of acellular vessels signif-
icantly increased (P  0.01) in diabetic rat retinas. In
addition, there was a signiﬁcant increase and reduction,
respectively, in the diabetic eyes treated with simvastatin
compared with untreated diabetic rats (P  0.01) (Fig.
2A–E). Concomitantly, in diabetic rat retinas, the activity
of p38 MAPK signiﬁcantly increased as compared with
those in the nondiabetic animals, and the changes were
signiﬁcantly inhibited by simvastatin (Fig. 2F). By immu-
nohistochemical analysis of trypsin-digested retinal blood
vessels, it was found that simvastatin signiﬁcantly de-
creased the activation of p38MAPK induced by diabetes
(Fig. 2G and supplementary data in the online appendix
available at http://diabetes.diabetesjournals.org/content/
early/2010/06/15/db10-0638/suppl/DC1). Pearson correla-
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FIG. 1. Changes of retinal VEGF levels in the control rats (control),
diabetic rats (DM), and diabetic rats treated with simvastatin
(DM  S). A: Real-time RT-PCR determination of VEGF mRNAs
relative to the control values. B: Western blot analysis of VEGF
protein expression in the three groups. Equal protein loading was
conﬁrmed by detection of -actin. C: Retinal vascular permeability
in the three groups. Bars indicate SD. A representative experiment of
the three is shown (**P < 0.01 vs. control; ##P < 0.01 vs. DM; n  8).
TABLE 1
Metabolic and physical parameters of the experimental groups
(24 weeks)
Control DM DM  S
Body weight (g) 581  53 388  31* 409  45*
Nonfasting blood
glucose (mmol/l) 4.6  0.3 26.2  5.3** 27.1  3.3**
24-hour urine volume
(ml) 21  5.2 203  56** 189  63**
Triglycerides (mg/dl) 103.6  9.3 146.8  11.6** 119  8.9#
Cholesterol (mg/dl) 89.6  5.2 154.5  9.8** 112.6  8.2##
**P  0.01 for the difference between the diabetic and nondiabetic
groups or between the nondiabetic and diabetic  simvastatin
groups; #P  0.05 for the difference between the diabetic and
diabetic  simvastatin groups; ##P  0.01 for the difference between
the diabetic and diabetic  simvastatin groups. Control, control rats;
DM, diabetic rats; DM  S, diabetic rats treated with simvastatin.
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the changes in apoptosis of retinal capillary cells and
acellular vessel formation and the changes in activity of
p38 MAPK in diabetic rats with or without simvastatin
treatment, respectively (data not shown).
Protective effect of simvastatin on retinopathy in
diabetic rats is associated with the inhibition of
PARP activity. PARP activity was demonstrated using a
mAb to detect poly(ADP-ribosyl)ated proteins, which is
the product of the enzyme. As illustrated in Fig. 3A,a
marked increase was observed in poly(ADP-ribosyl)ation
of the proteins obtained from the retinal extract of
6-month diabetic rats as compared with the nondiabetic
controls, and it was signiﬁcantly inhibited by simvastatin,
which was accompanied by upregulation of VEGF (Fig. 1A
and B) and activation of p38MAPK (Fig. 2F). Moreover, the
effects were similar to that with PJ-34 (data not shown). In
vitro, PJ-34 also signiﬁcantly inhibited VEGF expression
and activation of p38 MAPK and prevented the apoptosis
of BRECs incubated in HG, as did simvastatin (Fig. 3B and
C). In addition, we found that PARP antisense oligonucle-
otides downregulate VEGF expression (data not shown)
and inhibited the activation of p38 MAPK in BRECs (22).
These results suggest that the effect of simvastatin on
retinopathy in diabetic rats may be associated with the
inhibition of PARP activity.
PARP activation is mediated by mitochondrial ROS in
vivo and in vitro. Our study revealed that the production
of m and ROS was signiﬁcantly increased in the retinas
of diabetic rats compared with nondiabetic rats (P  0.01),
and simvastatin treatment reduced these effects (Fig. 4A
and C). Similarly, we found that in vitro exposure of
BRECs to HG increased m, ROS synthesis, and PARP
activity, upregulated VEGF, increased p38 MAPK activity,
and concomitantly induced the apoptosis of the cells;
however, these changes were signiﬁcantly inhibited by
simvastatin (Figs. 3B and C, Fig. 4B and D). Moreover, we
observed dosage-dependent effects of simvastatin on cell
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FIG. 2. Observation of the number of retinal capillary cells and activity of p38 MAPK in the control, DM, and DM  S groups. A and B: Low- and
high-magniﬁcation photomicrographs (50 and 400, respectively) of trypsin-digested retinal blood vessels obtained from the three groups. All
preparations were stained with PAS and hematoxylin; arrowheads indicate acellular capillary. C–E: Determination of pericyte/mm
2 of capillary
area (C), endothelial cell (EC)/mm
2 of capillary area (D), and acellular capillary segment/mm
2 in the retinal vessels (E) in the three groups. F:
Western blot analysis of activity of p38 MAPK (phosphorylation of p38 MAPK, p-p38 MAPK) in the three groups. Bars indicate SD. A
representative experiment of the three is shown (**P < 0.01 vs. control; ##P < 0.01 vs. DM; n  8). (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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p-p38MAPK in BRECs in serum-free DMEM containing HG
(Fig. 4E). As described in our previous study (23), local-
ization of ROS production was investigated in cultured
cells double-labeled with CM-H2DCFDA to detect ROS
production and MitoTracker Red CM-H2XRos (MTR; Mo-
lecular Probes) to visualize mitochondria. The results of
this study indicated that mitochondria are the major
source of ROS production after exposure to HG (data not
shown).
To test our hypothesis that ROS is an upstream mole-
cule of PARP/VEGF/p38MAPK pathway activation under
high glucose condition, we employed two approaches: one
with ROS scavengers NAC, and the other with exogenous
hydrogen peroxide (H2O2) (commonly used on behalf of
ROS). First, our results showed that NAC, a ROS scaven-
ger, prevented the activation of PARP, arrested the eleva-
tion of VEGF, and inhibited the activation of p38 MAPK
induced by hyperglycemia (Fig. 5A). Second, our results
indicated that incubation with H2O2 induced the activation
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0.5, 1.0, 5.0, 10.0 	mol/l) on cell apoptosis, ROS, poly(ADP-ribosyl)ated protein, VEGF, and p-p38MAPK in BRECs in serum-free DMEM containing
HG. Bars indicate SD. A representative experiment of the three is shown (**P < 0.01 vs. control, #P < 0.05 vs. DM, ##P < 0.01 vs. DM, n  8; **P <
0.01 vs. NG, ##P < 0.01 vs. HG, $P < 0.05 vs. HG  S, $$P < 0.01 vs. HG  S, n  9).
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MAPK activity. In addition, the effects were similar to that
by HG (Fig. 5B). Our results also demonstrated that the
effect of H2O2 on them was both time- and dosage-
dependent (data not shown). To rule out the inﬂuence of
osmolarity on ROS generation, mannitol was used to treat
the cells, but we found that mannitol had no effect (data
not shown).
Inhibition of p38 MAPK restores cell survival. To
conﬁrm the role of p38 MAPK activation in the proapop-
totic effects of HG or exogenous H2O2, we treated the cells
with the speciﬁc p38 MAPK inhibitor SB203580 (25 	mol/l)
and assessed apoptosis. The p38 MAPK inhibitor did not
affect cell death in the normal glucose control, but signif-
icantly reduced the apoptosis induced in HG-maintained
or exogenous H2O2 cultures (Fig. 6A and B).
Simvastatin reduces ROS production and inhibits the
activation of its downstream pathway through the
PGC-1 pathway. A previous study revealed that PGC-1
is a broad and powerful regulator of ROS metabolism (24).
To explore the mechanism underlying the inhibition of
mitochondrial ROS by simvastatin, PGC-1 was assayed.
In the present study, we ﬁrst found that PGC-1 mRNA
and protein expressions were signiﬁcantly decreased in
the retinas of diabetic rats compared with nondiabetic rats
(P  0.01), and simvastatin treatment inhibited this effect
(Fig. 7A and B). In vitro, simvastatin treatment not only
inhibited the downregulation of PGC-1 mRNA and pro-
tein expression in BRECs induced by HG, but also directly
upregulated the expression of PGC-1 mRNA and protein
under NG conditions (Fig. 7C and D). Moreover, the effects
of simvastatin on PGC-1 expression in BRECs incubated
by HG were offset by the addition of mevalonate; however,
Y27632, an inhibitor of Rho kinase, inhibited the HG-
induced PGC-1 downregulation, and the action was sim-
ilar to that with simvastatin (Fig. 7C and D).
We also found that the effect of simvastatin on m and
ROS production in BRECs incubated by hyperglycemia
were lost in cells infected with viruses expressing RNAi
directed against PGC-1 (Fig. 4B and D). Furthermore, the
PGC-1 null cells displayed a higher activation of PARP
and p38 MAPK, and upregulation of VEGF induced HG; in
contrast, under NG conditions, PGC-1 null cells showed
no deﬁnitive activation of PARP, p38 MAPK, and VEGF
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BRECs have a higher activation level of the mitochondrial
ROS pathway and a greater sensitivity to oxidative stress
induced by HG. Therefore, the inhibition of mitochondrial
ROS by simvastatin may be mediated by the PGC-1
pathway.
DISCUSSION
This study demonstrates, for the ﬁrst time, that simvasta-
tin can decrease the mitochondria-derived ROS generation
through the PGC-1 pathway, subsequently downregulat-
ing VEGF expression and blocking the activation of p38
MAPK through the inhibition of PARP activity in retinas of
diabetic rats and in BRECs incubated with HG. Concomi-
tantly, this leads to the alleviation in retinal vascular
permeability and reduction of apoptosis of retinal capillary
cells in diabetic rats.
Recent trials revealed lower coronary risk, despite com-
parable cholesterol levels, in patients treated with statins
compared with those in the placebo group (25). Statins
inhibit the synthesis of mevalonic acid, a precursor of
many nonsteroidal isoprenoid compounds such as farne-
sylpyrophosphate and geranylgeranylpyrophosphate (26).
In endothelial cells, farnesylation and geranylgeranylation
are responsible for the translocation of Ras and Rho from
the cytoplasm to the membrane, that is, the site of action
of these proteins (27). In the present study, we found that
simvastatin upregulated PGC-1 expression, subsequently
resulting in the decrease of m and ROS production in
retina in diabetic rats and in BRECs incubated by hyper-
glycemia. This action may be executed through the inhi-
bition of the synthesis of mevalonic acid since it was offset
by the addition of mevalonate. These results imply that the
effect of statins on PGC-1 expression is mediated by the
inhibition of the pathway from isoprenoid to small G
proteins. This is supported by the observation that Y27632
could mimic the effects of the statins.
The transcriptional coactivator PGC-1 was identiﬁed
through its functional interaction with the nuclear recep-
tor PPAR in brown adipose tissue (BAT), a mitochondria-
rich tissue specialized for thermogenesis (28). A PPAR-
responsive element is located in the distal region of the
PGC-1 gene promoter that binds PPAR/retinoid X recep-
tor heterodimers (29). In addition to BAT, PGC-1 is
strongly expressed in heart, skeletal muscle, kidney, and
brain, all of which are highly oxidative tissues (30–32).
PGC-1 is highly versatile and has the ability to interact
with many different transcriptional factors, including nu-
clear respiratory factors (NRF-1 and NRF-2), estrogen-
related receptor-, Gabpa/b, PPARs, and the thyroid
hormone receptor. These transcriptional factors support
mitochondrial biogenesis through the expression of genes
encoding proteins involved in oxidative phosphorylation,
fatty acid oxidation, heme biosynthesis, and mitochondrial
protein import (33).Through binding to and coactivating
different transcriptional factors, PGC-1 activates distinct
biologic processes in different tissues. For example, when
ectopically expressed in fat or muscle cells, PGC-1
strongly promotes increases in mitochondrial DNA as well
as expression of a large set of nuclear and mitochondrial-
encoded genes (30). Thus, PGC-1 initiates the elevation
of mitochondrial biogenesis and oxidative metabolism,
participates in the regulation of the downstream steps of
this biologic program, and is also involved in pathogenic
conditions such as obesity, diabetes, neurodegeneration,
and cardiomyopathy (34). In this study, we ﬁrst demon-
strated that PGC-1 was expressed in rat retina and in
BRECs, that diabetes and HG downregulate PGC-1, and
furthermore, that simvastatin inhibited these changes.
Upregulation of PGC-1 by simvastatin suppressed the
production of m and ROS, and the effects of simvastatin
on ROS were blocked by PGC-1 RNAi. In addition,
PGC-1 null BRECs displayed a greater sensitivity to
oxidative stress induced by HG. With respect to the
mechanisms underlying the action of PGC-1 on ROS, a
previous study demonstrated that PGC-1a induces the
classic ROS-scavenging enzymes by an oxidative stressor,
and importantly, the induction of anti-ROS genes is not
limited to those of the mitochondria; GPx1, catalase, and
SOD1 are all present substantially or totally in the nonmi-
tochondrial cytoplasm and peroxisomes (24). Also key is
the fact that PGC-1a can regulate the expression of UCP2
and UCP3, both of which are now understood to be
important regulators of ROS formation, as we and others
have demonstrated (11,24,35).
We also investigated the mechanism underlying the
effect of simvastatin on PGC-1a. BRECs were coincubated
with mevalonate or Y27632 (an inhibitor of Rho kinase) in
the presence of simvastatin. Mevalonate is a precursor for
cholesterol and isoprenoid intermediates such as farnesyl
pyrophosphate and geranylgeranyl pyrophosphate. The
isoprenoids are important lipid moieties added during
post-translational modiﬁcation of a variety of proteins,
including G-proteins and G-protein subunits, Ras, and
Ras-like proteins such as Rho, Rab, Rae, Ral, or Ra. Statins
inhibit the biosynthesis of mevalonate. In this present
study, we found that mevalonate prevented the effects of
simvastatin, suggesting that the observed effects of HMG-
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on the absence of mevalonate, but may not be entirely
related to cholesterol reduction. We also found that
Y27632 inhibits the HG-induced PGC-1 downregulation,
similarly to that with simvastatin, indicating that its effect
may be through the inhibition of Rho kinase.
As stated in the INTRODUCTION, HG in the endothelial cells
leads to overproduction of mitochondrial ROS, which
inactivates glyceraldehyde-3-phosphate dehydrogenase by
PARP activation and subsequent ADP ribosylation (14,15).
PARP is a family of eukaryotic nuclear enzymes and plays
an important role in regulating DNA repair, gene transcrip-
tion, cell cycle progression, chromatin function, genomic
stability, and cell death. However, excessive activation of
PARP represents a fundamental step in the pathogenesis
of numerous diseases and in diabetic complications
(14,15,36). A previous study revealed that PARP activation
is involved in diabetes- and hypoxia-induced VEGF pro-
duction, which is located downstream from sorbitol path-
way activation and oxidative stress (37). Recent evidence
from our previous study and a study of PARP knockout
mice suggests that PARP function is involved in signal
transduction, important in enhancing the p38/MAPK sig-
naling in response to HG or inﬂammatory stimulation
(22,38). In this study, our results revealed that PARP
activity was increased in the retinal tissues of diabetic rats
and simvastatin treatment inhibited PARP activation,
downregulated VEGF expression, and reduced the activa-
tion of p38 MAPK; the latter ﬁnding is consistent with the
report indicating that simvastatin attenuates blood retinal
barrier breakdown via VEGF suppression (3,6). Moreover,
it was found that p38 MAPK activity decreased concomi-
tantly with the retinal vascular cell apoptosis.
In the present study, ﬁrst, we found that ROS is an
upstream molecule of PARP, and this is in agreement with
previous studies (14,15) in which NAC, a ROS scavenger,
could inhibit hyperglycemia-induced activation of PARP,
whereas H2O2 increased PARP and p38 MAPK activity,
upregulated VEGF expression, and induced the apoptosis
of BRECs. Additionally, we found that VEGF expression
and p38 MAPK activity were mediated by PARP activity, as
the PARP inhibitor PJ-34 or PARP antisense oligonucleo-
tides downregulate VEGF expression in BRECs (data not
shown), and inhibited the activation of p38 MAPK and
HUVECs apoptosis (22). Finally, we found that the effects
of simvastatin on VEGF expression, p38 MAPK activity,
and cell apoptosis were associated with the suppression of
PARP activity since the action of simvastatin was similar
to that by PJ-34 or PARP antisense oligonucleotides.
VEGF, an angiogenic cytokine secreted by a variety of
cells, is a potent survival factor for endothelial cells in vivo
and in vitro (7). However, diabetes or HG treatment blocks
the prosurvival effect of VEGF and causes accelerated
endothelial cell apoptosis via the action of peroxynitrite in
causing tyrosine nitration of PI 3-kinase, inhibiting the
activity of Akt-1 kinase, and increasing the activity of p38
MAPK (39). In the present study, we found similar results
in that HG or H2O2 upregulated VEGF, increased the
activity of p38 MAPK, and induced the apoptosis of the
endothelial cell (data not shown). Furthermore, the action
of simvastatin in the apoptosis of BRECs was similar to
that by the speciﬁc p38 MAPK inhibitor SB203580. There-
fore, the upregulation of VEGF induced by hyperglycemia
leads to not only increased vascular permeability, but also
to the selective loss of pericytes and formation of acellular
capillaries by increasing the activity of p38 MAPK.
In conclusion, simvastatin alleviated retinal vascular
permeability and inhibited the apoptosis of retinal capil-
lary cells and formation of acellular capillaries in diabetic
rats through the inhibition of VEGF expression and p38
MAPK activity mediated by the PGC-1/mitochondrial
ROS/PARP pathway. These results suggest that statins
have potential clinical applications in the prevention and
treatment of mitochondrial oxidative stress-related illness
such as DR.
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